Abstract: Multi-dose ocular fluid delivery devices are provided. Aspects of the fluid delivery devices include a fluid package and an actuator. The fluid package includes a reservoir of an ophthalmic formulation, an aperture and a valve member for sealing the aperture when fluid is not being ejected therethrough. The actuator is configured to operate the valve member so as to at least reduce, if not prevent, ingress of outside materials or contaminants into the reservoir, such that the ophthalmic formulation present in the reservoir does not require a preservative (e.g., where a preservative-free ophthalmic formulation is present in the reservoir). Also provided are methods of using the devices in fluid delivery applications, as well as a kit that includes components of the devices.
Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.
Type:
Application
Filed:
September 21, 2022
Publication date:
September 21, 2023
Applicant:
NOVARTIS AG
Inventors:
Aida ABUJOUB, John BLANKENSHIP, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU
Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
September 19, 2023
Assignee:
Novartis AG
Inventors:
Gary Glick, Shomir Ghosh, William R. Roush
Abstract: The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection caused by varicella zoster virus and vaccinating the patient prior to administration of an S1P receptor modulator or agonist.
Type:
Grant
Filed:
January 10, 2020
Date of Patent:
September 19, 2023
Assignee:
Novartis AG
Inventors:
Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder, William C. Collins
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
September 12, 2023
Assignee:
Novartis AG
Inventors:
Ha-Soon Choi, Jiqing Jiang, James Paul Lajiness, Bao Nguyen, Hank Michael James Petrassi
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
Type:
Grant
Filed:
June 1, 2020
Date of Patent:
September 12, 2023
Assignee:
Novartis AG
Inventors:
Alexandra Marshall Bruce, Aaron Kanter, Aimee Richardson Usera, Jun Yuan, Frederic Zecri
Abstract: The invention provided herein includes pharmaceutical compositions comprising a TLR7 agonist having the structure of Formula (A), aluminum-containing particles, and one or more pharmaceutically acceptable excipient. The invention further provides the use of such compositions in the treatment of solid tumors either alone or in combination with one or more additional pharmaceutical compositions.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
September 12, 2023
Assignee:
Novartis AG
Inventors:
Michael Cooke, Shailaja Kasibhatla, Andrew T. Miller, Tom Yao-Hsiang Wu
Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.
Abstract: The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).
Type:
Grant
Filed:
September 2, 2016
Date of Patent:
September 5, 2023
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Inventors:
Alfred Garfall, Alex Ganetsky, Saar Gill, Simon Lacey, Jan J. Melenhorst, David Teachey, Eric Lancaster, Adam David Cohen, Pamela Shaw
Abstract: The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
August 15, 2023
Assignee:
Novartis AG
Inventors:
Jörg Eder, Richard Alexander Harrison, Boerje Haraldsson, Anna Svenja Schubart
Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
Type:
Grant
Filed:
October 7, 2021
Date of Patent:
August 15, 2023
Assignee:
Novartis AG
Inventors:
Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler
Abstract: The invention features methods of identifying patients as being likely to respond to anti-VEGF therapy. Furthermore, in those patients identified as failing to include one or more of the above ophthalmic response markers, the invention features treatment with an EPO antagonist (e.g., alone, or in combination with a VEGF antagonist).
Abstract: The invention relates, in part, to methods of scoring a sample containing tumor tissue from a cancer patient. The score is representative of a spatial proximity between at least one pair of cells, a first member of the at least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.
Type:
Grant
Filed:
June 2, 2020
Date of Patent:
August 15, 2023
Assignee:
Novartis AG
Inventors:
Naveen Dakappagari, Thai Tran, Brian Little, Ju Young Kim, Jennifer Bordeaux
Abstract: A cell bag rotator is constructed to slowly agitate a plurality of cell bags by rotation along a rotation axis that is at least partially horizontal. The cell bag rotator comprises a plurality of plates to which a respective cell bag is attached. The cell bag rotator is suitable for mixing cells with particles for performing various types of subsequent cell therapy processes on the cells.
Type:
Grant
Filed:
October 14, 2021
Date of Patent:
August 8, 2023
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
August 8, 2023
Assignee:
Novartis AG
Inventors:
Shankar Venkatraman, Shomir Ghosh, William R. Roush, Dong-Ming Shen, Jason Katz, Hans Martin Seidel
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Grant
Filed:
August 12, 2021
Date of Patent:
July 25, 2023
Assignee:
Novartis AG
Inventors:
Mallesh Bushaboina, Xin Chen, Atwood Kim Cheung, Andrew James Culshaw, Timothy Brian Hurley, Nancy Labbe-Giguere, Wolfgang Miltz, David Orain, Tajesh Patel, Srinivasan Rajagopalan, Till Roehn, David Andrew Sandham, Gebhard Thoma, Ritesh Bhanudasji Tichkule, Rudolf Wälchli
Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.
Type:
Grant
Filed:
December 23, 2019
Date of Patent:
July 25, 2023
Assignees:
Novartis AG, The Medical College of Wisconsin, Inc.
Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
Type:
Grant
Filed:
December 17, 2020
Date of Patent:
July 18, 2023
Assignee:
NOVARTIS AG
Inventors:
Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken